Tien Liang Biotech (4127) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 天良

Tien Liang Biotech (4127) reported revenue of NT$44.1 million for Oct 2026, +2.3% year on year and -22.6% from the previous month. Revenue for Jan–Oct 2026 was NT$597.7 million (+40.7% year on year).

Year-on-year revenue growth: 21 months in a row. →

In Oct 2026, it ranked No. 103 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$29.3 million24/10Nov 2024 NT$32.9 millionDec 2024 NT$25.2 millionJan 2025 NT$39.1 millionFeb 2025 NT$32.6 million25/02Mar 2025 NT$45.4 millionApr 2025 NT$41.2 millionMay 2025 NT$47.7 millionJun 2025 NT$39.2 million25/06Jul 2025 NT$47.1 millionAug 2025 NT$38.9 millionSep 2025 NT$51.4 millionOct 2025 NT$43.1 million25/10Nov 2025 NT$44.4 millionDec 2025 NT$44.1 millionJan 2026 NT$53.6 millionFeb 2026 NT$77.9 million26/02Mar 2026 NT$66.7 millionApr 2026 NT$68.7 millionMay 2026 NT$60.6 millionJun 2026 NT$55.4 million26/06Jul 2026 NT$58.9 millionAug 2026 NT$54.8 millionSep 2026 NT$57 millionOct 2026 NT$44.1 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$44.1 million+2.3%-22.6%
Sep 2026NT$57 million+10.9%+4.0%
Aug 2026NT$54.8 million+40.8%-7.0%
Jul 2026NT$58.9 million+25.2%+6.3%
Jun 2026NT$55.4 million+41.4%-8.5%
May 2026NT$60.6 million+27.0%-11.9%
Apr 2026NT$68.7 million+66.8%+3.0%
Mar 2026NT$66.7 million+47.1%-14.4%
Feb 2026NT$77.9 million+139.1%+45.4%
Jan 2026NT$53.6 million+37.1%+21.5%
Dec 2025NT$44.1 million+75.0%-0.8%
Nov 2025NT$44.4 million+35.0%+3.1%
Oct 2025NT$43.1 million+47.1%-16.1%
Sep 2025NT$51.4 million+70.5%+32.1%
Aug 2025NT$38.9 million+19.4%-17.4%
Jul 2025NT$47.1 million+35.5%+20.0%
Jun 2025NT$39.2 million+56.9%-17.7%
May 2025NT$47.7 million+60.2%+15.7%
Apr 2025NT$41.2 million+44.8%-9.1%
Mar 2025NT$45.4 million+70.8%+39.1%
Feb 2025NT$32.6 million+4.3%-16.6%
Jan 2025NT$39.1 million-28.9%+55.1%
Dec 2024NT$25.2 million-31.2%-23.4%
Nov 2024NT$32.9 million-9.3%+12.3%
Oct 2024NT$29.3 million-35.2%-2.7%

Jan–Oct 2026 cumulative: NT$597.7 million (+40.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Tien Liang Biotech vs PEC / Tien Liang Biotech vs Lotus Pharm / Tien Liang Biotech vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16